General description
Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1). Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5)
Application
Glipizide has been used in:
- chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assay
- MCF-7 breast cancer assay on chorioallantoic membrane (CAM)
- metastasis assays
- rat aortic ring assay
- in vivo matrigel plug assay
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
- flow cytometry
- western blotting
Biochem/physiol Actions
Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance. It is an ATP-dependent K+ channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC). Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes. Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis.
Features and Benefits
This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
- UPC:
- 51184009
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- G117-500MG
- CAS:
- 29094-61-9
